BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Remternetug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Remternetug\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06653153-669@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Remternetug: Phase 3 readout est. (NCT06653153)
DESCRIPTION:Remternetug\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)\
 nEstimated primary completion: April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/remternetug#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06653153
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647498-669@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20340331
DTEND;VALUE=DATE:20340401
SUMMARY:Remternetug: Phase 2/3 readout est. (NCT06647498)
DESCRIPTION:Remternetug\, phase 2/3\, Alzheimer's Disease.\nStudy: A Study 
 of a Potential Disease Modifying Treatment in Individuals at Risk for or W
 ith a Type of Early Onset AD Caused by a Genetic Mutation\nEstimated prima
 ry completion: March 2034. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/remternetug#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06647498
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552157-669@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20340330
DTEND;VALUE=DATE:20340331
SUMMARY:Remternetug: Phase 2/3 readout est. (NCT05552157)
DESCRIPTION:Remternetug\, phase 2/3\, Alzheimer's Disease.\nStudy: A Study 
 of Potential Disease Modifying Treatments in Individuals at Risk for or Wi
 th a Type of Early Onset AD Caused by a Genetic Mutation\nEstimated primar
 y completion: 30 March 2034. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/remternetug#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05552157
URL:https://assetmemo.bio/drug/remternetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
